Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies on August 10, 2026 acquisition Actio Biosciences Epilepsy Infrequent Jazz KCNT1 gene +
Regeneron Leads $66M Series B for Actio Biosciences’ Rare Disease Therapeutics on June 19, 2025 ABS-0871 ABS-1230 Actio Biosciences Charcot-Marie-Tooth Disease Clinical Trials Drugs, Orphan Epilepsy Infrequent Inhibitor KCNT1 gene Regeneron Series B financing TRPV4 protein, human +